PMID- 24932223
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140616
LR  - 20220410
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 6
DP  - 2014
TI  - Post-meal beta-cell function predicts the efficacy of glycemic control in patients 
      with type 2 diabetes inadequately controlled by metformin monotherapy after 
      addition of glibenclamide or acarbose.
PG  - 68
LID - 10.1186/1758-5996-6-68 [doi]
AB  - BACKGROUND: This study aimed to explore parameters which will predict good 
      control of HbA1c after adding a second anti-diabetic drug in patients with type 2 
      diabetes mellitus (T2DM) inadequately controlled with metformin monotherapy. 
      METHODS: Fifty-one patients (M/F: 25/26, mean age: 53.7 +/- 8.2 years, mean 
      glycated hemoglobin [HbA1c] 8.4 +/- 1.2%) with T2DM inadequately controlled with 
      metformin were randomized to add-on glibenclamide or acarbose for 16 weeks. 
      Before and after combination therapy, the subjects underwent a 2-hour liquid 
      mixed meal tolerance test to determine insulin secretion (HOMA-beta, insulinogenic 
      index, and disposition index [DI]) and insulin sensitivity (HOMA-IR and Matsuda 
      insulin sensitivity index). RESULTS: At baseline, there was a significant inverse 
      relationship between DI120 and HbA1c (p = 0.001) in all subjects. The addition of 
      glibenclamide and acarbose improved HbA1c significantly from 8.6 +/- 1.6% to 
      7.4 +/- 1.2% (p < 0.001), and from 8.2 +/- 0.8% to 7.5 +/- 0.8% (p < 0.001), 
      respectively. In the glibenclamide group, DI120 significantly increased from 
      51.2 +/- 24.2 to 74.9 +/- 41.9 (p < 0.05), and in the acarbose group, from 
      62.5 +/- 31.4 to 91.7 +/- 36.2 (p < 0.05), respectively. Multiple regression analyses 
      showed that both baseline HbA1c and DI120 independently predicted reduction of 
      HbA1c as well as final HbA1c after combination therapy. CONCLUSIONS: In patients 
      with T2DM inadequately controlled with metformin, add-on oral anti-diabetic agent 
      with glibenclamide or acarbose resulted in the significant HbA1c reduction and 
      improvement of beta-cell function. Subjects with greater baseline beta-cell function 
      reserve displayed better glycemic response in the combination therapy of 
      metformin with glibenclamide or acarbose. TRIAL REGISTRATION: This study was 
      registered in the ClinicalTrials.gov with registration number of NCT00417729.
FAU - Chen, Po-Hsun
AU  - Chen PH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Taichung Veterans General Hospital, No. 1650, Sect. 4, Taiwan Boulevard, Taichung 
      40705, Taiwan.
FAU - Tsai, Yi-Ting
AU  - Tsai YT
AD  - Department of Internal Medicine, Taichung Veterans General Hospital, Chiayi 
      branch, Chiayi, Taiwan.
FAU - Wang, Jun-Sing
AU  - Wang JS
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Taichung Veterans General Hospital, No. 1650, Sect. 4, Taiwan Boulevard, Taichung 
      40705, Taiwan.
FAU - Lin, Shi-Dou
AU  - Lin SD
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Changhua Christian Hospital, Changhua, Taiwan.
FAU - Lee, Wen-Jane
AU  - Lee WJ
AD  - Department of Medical Research, Taichung Veterans General Hospital, Taichung, 
      Taiwan.
FAU - Su, Shih-Li
AU  - Su SL
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Changhua Christian Hospital, Changhua, Taiwan.
FAU - Lee, I-Te
AU  - Lee IT
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Taichung Veterans General Hospital, No. 1650, Sect. 4, Taiwan Boulevard, Taichung 
      40705, Taiwan.
AD  - School of Medicine, College of Medicine, National Yang-Ming University, Taipei, 
      Taiwan.
FAU - Tu, Shih-Te
AU  - Tu ST
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Changhua Christian Hospital, Changhua, Taiwan.
FAU - Tseng, Yao-Hsien
AU  - Tseng YH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Taichung Veterans General Hospital, No. 1650, Sect. 4, Taiwan Boulevard, Taichung 
      40705, Taiwan.
FAU - Sheu, Wayne H-H
AU  - Sheu WH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Taichung Veterans General Hospital, No. 1650, Sect. 4, Taiwan Boulevard, Taichung 
      40705, Taiwan.
AD  - School of Medicine, College of Medicine, National Yang-Ming University, Taipei, 
      Taiwan.
AD  - Department of Medicine, National Defense Medical Center, Taipei, Taiwan.
AD  - Institute of Medical Technology, College of Life Science, National Chung-Hsing 
      University, Taichung, Taiwan.
FAU - Lin, Shih-Yi
AU  - Lin SY
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Taichung Veterans General Hospital, No. 1650, Sect. 4, Taiwan Boulevard, Taichung 
      40705, Taiwan.
AD  - School of Medicine, College of Medicine, National Yang-Ming University, Taipei, 
      Taiwan.
LA  - eng
SI  - ClinicalTrials.gov/NCT00417729
PT  - Journal Article
DEP - 20140531
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC4057801
OTO - NOTNLM
OT  - Beta-cell function
OT  - Disposition index
OT  - Glycated hemoglobin
OT  - Glycemic control
OT  - Metformin
EDAT- 2014/06/17 06:00
MHDA- 2014/06/17 06:01
PMCR- 2014/05/31
CRDT- 2014/06/17 06:00
PHST- 2014/02/20 00:00 [received]
PHST- 2014/05/26 00:00 [accepted]
PHST- 2014/06/17 06:00 [entrez]
PHST- 2014/06/17 06:00 [pubmed]
PHST- 2014/06/17 06:01 [medline]
PHST- 2014/05/31 00:00 [pmc-release]
AID - 1758-5996-6-68 [pii]
AID - 10.1186/1758-5996-6-68 [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2014 May 31;6:68. doi: 10.1186/1758-5996-6-68. eCollection 
      2014.